- Public Comps
- Daxor
Daxor Valuation Multiples
Discover revenue and EBITDA valuation multiples for Daxor and similar public comparables like K Pharma, FluoGuide, Rapid Micro Biosystems, Pangaea Oncology and more.
Daxor Overview
About Daxor
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Founded
1971
HQ

Employees
12
Website
Financials (LTM)
EV
$61M
Valuation Multiples
Start free trialDaxor Financials
Daxor reported last 12-month revenue of $8M.
In the same LTM period, Daxor generated $6M in gross profit and had net loss of ($921K).
Revenue (LTM)
Daxor P&L
In the most recent fiscal year, Daxor reported revenue of $10M and net income of $9M.
Daxor is profitable as of last fiscal year, with gross margin of 81% and net margin of 89%.
Financial data powered by Morningstar, Inc.
Daxor Stock Performance
Daxor has current market cap of $61M, and enterprise value of $61M.
Market Cap Evolution
Daxor's stock price is $10.46.
Daxor share price increased by 3.8% in the last 30 days, and decreased by 24.0% in the last year.
Daxor has an EPS (earnings per share) of $1.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $61M | $61M | 1.9% | 3.8% | 1.6% | -24.0% | $1.57 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDaxor Valuation Multiples
Daxor trades at 7.2x EV/Revenue multiple.
EV / Revenue (LTM)
Daxor Financial Valuation Multiples
As of September 9, 2026, Daxor has market cap of $61M and EV of $61M.
Daxor has a P/E ratio of (66.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Daxor Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Daxor Margins & Growth Rates
Daxor decreased revenue by 10% and net profit by 113% in the last fiscal year.
In the most recent fiscal year, Daxor reported gross margin of 81% and net margin of 89%.
Daxor Margins
Daxor Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Daxor Operational KPIs
Daxor's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Daxor Competitors
Daxor competitors include K Pharma, FluoGuide, Rapid Micro Biosystems, Pangaea Oncology, Theraclion, Bactiguard, Outset Medical, Osang Healthcare, Atlantic International and Envoy Medical.
Most Daxor public comparables operate across Medical Devices, Laboratory Services, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | (9.1x) | - | |||
| - | 4855.6x | (8.4x) | (6.9x) | |||
| 1.9x | 1.7x | (1.5x) | (1.6x) | |||
| 4.0x | 3.9x | (60.7x) | (20.9x) | |||
| 44.3x | - | (8.8x) | - | |||
| 3.1x | 3.1x | 16.7x | 21.2x | |||
| 0.2x | 0.2x | (0.3x) | (0.5x) | |||
| 0.7x | - | 8.3x | - | |||
This data is available for Pro users. Sign up to see all Daxor competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Daxor
| When was Daxor founded? | Daxor was founded in 1971. |
| Where is Daxor headquartered? | Daxor is headquartered in United States. |
| How many employees does Daxor have? | As of today, Daxor has over 12 employees. |
| Who is the CEO of Daxor? | Daxor's CEO is Michael R. Feldschuh. |
| Is Daxor publicly listed? | Yes, Daxor is a public company listed on Nasdaq. |
| What is the stock symbol of Daxor? | Daxor trades under DXR ticker. |
| When did Daxor go public? | Daxor went public in 1983. |
| Who are competitors of Daxor? | Daxor main competitors include K Pharma, FluoGuide, Rapid Micro Biosystems, Pangaea Oncology, Theraclion, Bactiguard, Outset Medical, Osang Healthcare, Atlantic International, Envoy Medical. |
| What is the current market cap of Daxor? | Daxor's current market cap is $61M. |
| What is the current revenue of Daxor? | Daxor's last 12 months revenue is $8M. |
| What is the current revenue growth of Daxor? | Daxor revenue growth (NTM/LTM) is 67%. |
| What is the current EV/Revenue multiple of Daxor? | Current revenue multiple of Daxor is 7.2x. |
| Is Daxor profitable? | No, Daxor is not profitable. |
| What is the current net income of Daxor? | Daxor's last 12 months net income is ($921K). |
| How many companies Daxor has acquired to date? | Daxor hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Daxor has invested to date? | Daxor hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Daxor
Lists including Daxor
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




